Table 2.

Gene-Agnostic Gene and Genetic Therapy Clinical Trials for IRDs and AMD

Disease Target	Product	Modality	Phase	Sponsor	NCT Number
Retinitis pigmentosa/LCA	OCU400 AAV.hNr2e3	Gene therapy	1/2	Ocugen	NCT05203939
Rod-cone dystrophy	SPVN06/AAV-RdCVF-RdCVFL	Gene therapy	1/2	SparingVision	NCT05748873
Stargardt disease	OCU410ST/AAV5.hRORA	Gene therapy	1/2	Ocugen	NCT05956626
Non-neovascular AMD	VOY-101	Gene therapy	1/2a	Perceive Biotherapeutics	NCT06087458
	AAVCAGsCD59	Gene therapy	2	Janssen	NCT03144999
	OCU410ST/AAV5.hRORA	Gene therapy	1/2	Ocugen	NCT06018558
	Ionis-FB-LRx	Antisense oligonucleotide	2	Ionis	NCT03446144
	Ionis-FB-LRx	Antisense oligonucleotide	2	Ionis	NCT03815825
	GT005	Gene therapy	1/2	Gyroscope	NCT03846193
Neovascular AMD	RGX-314	Gene therapy	1/2	REGENXBIO	NCT03066258
	RGX-314	Gene therapy	2/3	REGENXBIO/AbbVie	NCT04704921
	RGX-314	Gene therapy	3	REGENXBIO/AbbVie	NCT05407636
	SKG0106	Gene therapy	1/2	Skyline Therapeutics	NCT05986864 NCT06213038
	4D-150	Gene therapy	1/2	4DMT	NCT05197270
	ADVM-022	Gene therapy	2	Adverum	NCT05536973

Note: Inclusion in this table does not necessarily indicate that a trial is active.